Sarah Lee

Dr. Sarah Lee

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
JCJing-Yi Chern
Jing-Yi Chern
SLSarah Lee
Sarah Lee
MFMelissa K. Frey
Melissa K. Frey
JLJessica Lee
Jessica Lee
SBStephanie V. Blank
Stephanie V. Blank
Chern JY, et al. J Gynecol Oncol. 2018 Aug;30:e60. https://doi.org/10.3802/jgo.2019.30.e60

13 August 2020 in Journal of Assisted Reproduction and Genetics
Verified
Journal Article
Closed access
PDF file
SLSarah Lee
Sarah Lee
MSMegan Sutter
Megan Sutter
SLShelley Lee
Shelley Lee
MSMindy R. Schiffman
Mindy R. Schiffman
YKYael G. Kramer
Yael G. Kramer
FLFrederick Licciardi
Frederick Licciardi

24 September 2023 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
SLSarah Lee
Sarah Lee
ADAndreea I. Dinicu
Andreea I. Dinicu
LALikolani Arthurs
Likolani Arthurs
DSDanielle Shields
Danielle Shields
BPBhavana Pothuri
Bhavana Pothuri
MLMichelle Lightfoot
Michelle Lightfoot

15 July 2025 in Gynecologic Oncology
Verified
Journal Article
Closed access
SLSarah Lee
Sarah Lee
ASAngeles Alvarez Secord
Angeles Alvarez Secord
SFSteven Friedman
Steven Friedman
EHErinn M. Hade
Erinn M. Hade
CSCarson Smitherman
Carson Smitherman
BPBhavana Pothuri
Bhavana Pothuri

24 July 2023 in International Journal of Gynecological Cancer
Verified
Journal Article
Open access
PDF file
SLSarah Lee
Sarah Lee
CWChristopher R. Weil
Christopher R. Weil
LBLeslie R. Boyd
Leslie R. Boyd
CDCristina DeCesaris
Cristina DeCesaris
DGDavid Gaffney
David Gaffney
GSGita Suneja
Gita Suneja
Objective To explore the use of Gynecologic Oncology Group 258 (GOG 258) study regimens before, during, and after the study. Methods Patients aged 18 years or older with endometrial cancer between 2004–2019 were identified in the National Cancer Database. Inclusion criteria were stage III or IVA of any histology and stage I–IVA clear cell or serous histologies with positive washings that received adjuvant therapy. Adjuvant therapy use was examined in the pre-GOG 258 era (before 2009), during GOG 258 enrollment and maturation (2010–2017), and after results presentation in 2017 (2018–2019). Two-sided Cochran–Armitage tests, Wilcoxen rank sum tests, and χ2 tests were used for continuous and categorical variables. Multi-variable logistic regression assessed factors associated with the receipt of chemoradiotherapy compared with chemotherapy only or radiation therapy only. Results From 2004 to 2019, 41 408 high-risk endometrial cancer patients received adjuvant therapy (12% radiation therapy, 38% chemotherapy, 50% chemoradiotherapy). Chemoradiotherapy increased over the GOG 258 study period (40% before study opening, 54% during enrollment, and 59% after results). Serous (OR 0.6, 95% CI 0.6 to 0.7) and clear cell histology (0.7, 0.6 to 0.8), higher grade (0.8, 0.7 to 0.9), and lymph node positivity (0.8, 0.7 to 0.9) were negatively associated with receipt of chemoradiotherapy compared with single-modality treatment. Non-Hispanic Black ethnicity (0.8, 0.8 to 0.9) and residing ≥50 miles from the treatment facility (0.8, 0.7 to 0.9) were also negatively associated with chemoradiotherapy. Private insurance (1.2, 1.0 to 1.4) and treatment at community hospitals (1.2, 1.2 to 1.3) were positively associated with chemoradiotherapy. Conclusion Despite the lack of benefit in the GOG 258 experimental arm, chemoradiotherapy use increased during study enrollment and after results publication.

1 November 2025 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
SLSarah Lee
Sarah Lee
KBKara Banson
Kara Banson
HKHarika Koduru
Harika Koduru
ABAmnon Berger
Amnon Berger
OIOmar Ishaq
Omar Ishaq
SLStella C. Lymberis
Stella C. Lymberis